Relapsing Multiple Sclerosis (RMS) Latest Advances

Find the Latest Research About Relapsing Multiple Sclerosis (RMS)

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11637 publications

From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.

From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.

Journal: Journal of medical economics

Published: June 24, 2026

Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two‑year Phase IV CLARIFY‑MS Study.

Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two‑year Phase IV CLARIFY‑MS Study.

Journal: Neurology and therapy

Published: June 01, 2026

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: May 31, 2026

An Exploratory Cross-Sectional Study of the Association Between Regular Cigarette Smoking and Level of Disability, Hand Dexterity, Cognitive Impairment, Fatigue, and Markers of Oxidative Stress in Male Patients With Relapsing-Remitting Multiple Sclerosis.

An Exploratory Cross-Sectional Study of the Association Between Regular Cigarette Smoking and Level of Disability, Hand Dexterity, Cognitive Impairment, Fatigue, and Markers of Oxidative Stress in Male Patients With Relapsing-Remitting Multiple Sclerosis.

Journal: American journal of men's health

Published: May 31, 2026

Integrated pharmacological and Omega-3 therapy modulates immunometabolic pathways and neuro-ophthalmological outcomes in relapsing-remitting multiple sclerosis.

Integrated pharmacological and Omega-3 therapy modulates immunometabolic pathways and neuro-ophthalmological outcomes in relapsing-remitting multiple sclerosis.

Journal: Immunotherapy

Published: May 27, 2026

Data Quality in the ProVal-MS Study: Challenges and Lessons Learned.

Data Quality in the ProVal-MS Study: Challenges and Lessons Learned.

Journal: Studies in health technology and informatics

Published: May 23, 2026

Real-world experience with rituximab for multiple sclerosis treatment in a Brazilian tertiary center.

Real-world experience with rituximab for multiple sclerosis treatment in a Brazilian tertiary center.

Journal: Arquivos de neuro-psiquiatria

Published: May 18, 2026

Functional Connectivity Alterations of the Central Autonomic Network in Multiple Sclerosis: Links to Fatigue and Aerobic Training Effects.

Functional Connectivity Alterations of the Central Autonomic Network in Multiple Sclerosis: Links to Fatigue and Aerobic Training Effects.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: May 12, 2026

Uncoupling Relapse Reduction and Disability Progression: Evidence From Tolebrutinib Studies.

Uncoupling Relapse Reduction and Disability Progression: Evidence From Tolebrutinib Studies.

Journal: Neurology. Clinical practice

Published: May 11, 2026

Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Naïve Patients and Switchers in a Multicenter Cohort.

Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Naïve Patients and Switchers in a Multicenter Cohort.

Journal: Drugs - real world outcomes

Published: May 07, 2026

Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.

Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.

Journal: Neurology

Published: May 05, 2026

Intrathecal Mesenchymal Stem Cells in Progressive Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial (SMART-MS).

Intrathecal Mesenchymal Stem Cells in Progressive Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial (SMART-MS).

Journal: Neurology

Published: May 04, 2026

Showing 1-12 of 11,637

Last Updated: 06/30/2026